文献速递银屑病与炎症性皮肤病

西班牙银屑病患者特征:MAPP调查欧洲亚组分析

A European subset analysis from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis shows country-specific features: results from psoriasis patients in Spain.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2017-04-25

基于2012年6-8月MAPP调查中西班牙354例自报银屑病(无银屑病关节炎)患者与法、德、意、英共1700例患者的比较,西班牙患者平均BMI更高(26.9 vs 25.6,P≤0.001)、抑郁患病率更低(6% vs 12%,P=0.002)、自感最重时严重度更高(5.92 vs 5.33,P<0.001),但估算体表面积受累更低,平均DLQI总分更低(4.70 vs 6.06,P=0.001),就诊多位医疗提供者及达到治疗目标的比例更高。

要点

  • 西班牙患者自感严重度更高但DLQI更低,提示文化因素影响疾病感知。
  • 掌跖、甲、头皮银屑病在西班牙报告较少,但与更高DLQI相关。
  • 西班牙患者就诊多位医疗提供者及达到治疗目标比例更高,但当前治疗与其他欧洲国家相似。

核心结论

  • 西班牙银屑病患者在合并症、皮损范围与分布、严重度感知及生活质量影响方面与其他欧洲国家存在差异。
  • 西班牙患者自感严重度更高但估算体表面积受累更低,DLQI评分显著更低。
  • 西班牙患者就诊多位医疗提供者更多、达到治疗目标比例更高,当前治疗与其他欧洲国家相似。

研究设计与样本

  • MAPP调查于2012年6月至8月开展,本分析纳入1700例自报银屑病(无银屑病关节炎)患者。
  • 患者来自法国(n=349)、德国(n=311)、意大利(n=359)、西班牙(n=354)和英国(n=327)。
  • 西班牙患者与其他欧洲国家患者进行比较分析。

主要发现

  • 西班牙患者平均BMI为26.9,其他欧洲国家为25.6(P≤0.001)。
  • 西班牙患者抑郁患病率为6%,其他欧洲国家为12%(P=0.002)。
  • 西班牙患者自感最重时银屑病严重度为5.92,其他欧洲国家为5.33(P<0.001),尽管估算体表面积受累更低。
  • 西班牙患者平均DLQI总分为4.70,其他欧洲国家为6.06(P=0.001);各DLQI维度平均分均更低(均P<0.001,休闲、治疗、工作和学校分别为P=0.002、P=0.002、P=0.005)。
  • 掌跖、甲和头皮银屑病在西班牙患者中报告较少(P=0.026),且与更高DLQI值相关(P<0.01);西班牙患者就诊多位医疗提供者更多(P<0.001)且达到治疗目标更多(P<0.001)。

关键数值与推荐

  • DLQI值越高与年龄呈负相关,与自感严重度呈正相关。
  • 西班牙患者掌跖、甲和头皮银屑病报告较少(P=0.026),这些部位受累与更高DLQI值相关(P<0.01)。
  • 西班牙患者就诊多位医疗提供者更多(P<0.001)且达到治疗目标更多(P<0.001),当前治疗与其他欧洲国家相似。

临床怎么用

  • 评估西班牙银屑病患者时应关注其自感严重度较高但DLQI较低的特点,避免仅凭DLQI低估疾病负担。
  • 掌跖、甲和头皮受累与更高DLQI相关,临床应重视这些特殊部位评估。
  • 西班牙患者就诊多位医疗提供者及达到治疗目标比例更高,提示医疗可及性差异可能影响疾病管理。

局限性

  • MAPP调查数据为患者自报,未针对欧洲各国文化与医疗体系差异进行分析。
  • 本研究为西班牙亚组分析,样本仅来自五个欧洲国家。
  • 原文未报告随访时长、失访率及多变量校正结果等局限性信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey data were not analysed to account for cultural and healthcare system differences across European countries (EC). OBJECTIVE: To utilize MAPP data to characterize psoriasis in Spanish patients, including severity assessment and Dermatology Life Quality Index (DLQI). METHODS: The MAPP survey was conducted between June and August 2012. This analysis included 1700 patients with self-reported psoriasis (without psoriatic arthritis) from France (n = 349), Germany (n = 311), Italy (n = 359), Spain (n = 354) and the United Kingdom (n = 327). RESULTS: Patients from Spain vs. other EC self-reported higher mean body mass index (26.9 vs. 25.6, P ≤ 0.001), lower prevalence of depression (6% vs. 12%, P = 0.002) and higher mean self-perceived psoriasis severity at its worst (5.92 vs. 5.33, P < 0.001) despite lower estimated body-surface-area involvement. Overall, patients from Spain vs. other EC had lower mean global DLQI scores (4.70 vs. 6.06, P = 0.001) and lower mean scores for each DLQI dimension [all P < 0.001, except leisure (P = 0.002), treatment (P = 0.002), and work and school (P = 0.005)]. Higher DLQI values were inversely associated with age and directly correlated with perceived severity. Palmoplantar, nail and scalp psoriasis were reported less frequently in Spanish patients (P = 0.026) and were associated with higher DLQI values (P < 0.01). Spanish patients were more likely to have seen multiple healthcare providers (HCPs; P < 0.001) and achieve therapeutic goals (P < 0.001), but current treatments were similar to patients in other EC. CONCLUSIONS: In the MAPP survey, Spanish patients differed from other EC in several characteristics, including comorbidities, extent and distribution of psoriasis lesions, perception of severity and impact on quality of life. Their perception of psoriasis severity was higher despite a lower estimated extent, and DLQI scores were significantly lower. Spanish patients had more HCP visits and a higher rate of therapeutic goal achievement. These differences might be attributed to cultural factors, phenotypical variation and differences in HCP access.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Puig L, van de Kerkhof PCM, Reich K, et al. A European subset analysis from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis shows country-specific features: results from psoriasis patients in Spain. J Eur Acad Dermatol Venereol. 2017. PMID: 28271561. doi:10.1111/jdv.14195

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。